Fill and Finish Operations - - BioPharm International


Fill and Finish Operations

BioPharm International

Product stability needs to be tested before and after storage at various times, temperatures, and humidity. Stability-indicating parameters include pH, color, clarity, protein concentration determined by UV spectroscopy or enzyme-linked immunosorbent assays (ELISAs) for vapor transmission; protein bioactivity bioassays; the presence of protein fragments and aggregates by gel chromatography; and percent of deamidation by tryptic mapping. Other tests can be performed on container-closure integrity, preservative efficacy, changes from upright or inverted handling, package or stopper extractables, in-use tests, and test product remaining after in-use periods. Global climate zones and regulatory conditions require that therapeutics planned for other countries anticipate region-specific registration requirements.

Costs Campaign manufacturing is a critical economic concept that allows sequential manufacturing of different products in the same facility so that common facilities and equipment can be used for multiple products. Because of economies of scale, lower unit costs result from larger volumes, and smaller-volume products will have a lower cost of goods if they are produced in a shared or multiuse facility. Expenses in production include facilities, utilities, validation, containment, raw materials, labor, royalties, depreciation, insurance, and rent.

Multiproduct facilities can be subject to operations congestion, process equipment contamination, airborne contamination, increased staff activities, and increased regulatory caution. Factors involved in economic multiproduct finishing and filling include facility siting, operational efficiency, dedicated equipment, validation contingencies, flow separation, materials storage, product transfers, personnel access, and gowning and pass-through air locks. Such working environment considerations as flooring, walls, ceiling, and fixed furniture must be considered. Cell banking, seed preparation laboratories, fermentation media and preparatory formulation, harvest product recovery, purification, buffer preparation, product formulation rooms, product filling, lyophilization, labeling and packaging, quality laboratories, instrument calibration, routine maintenance work space, and equipment washing are all factors in product validation.

Freezing and lyophilization provide a cost savings by allowing product to be pooled into larger and fewer lots. Production-scale bulk can be frozen and thawed multiple times and sampled at intervals to extend its expiration date with adequate testing. Shipping and storing at subzero temperatures may not be technically or economically feasible in many markets — Europe does not guarantee refrigerated delivery, so lyophilization may be the most cost-effective choice for global distribution to a wider market. The goal is to design the fastest and most robust cycle possible, consuming the least amount of energy without affecting product quality.

BFS is an attractive economic alternative to glass vials because the process is streamlined and usually requires no preservatives or antimicrobials. Capital costs may be less than those for equipment and facilities needed to sterilize components and the processes to fill, stopper, and cap glass vials. BFS machines can form, fill, and seal a set of containers in 12 seconds. Scale-up is accomplished by increasing the number of mold cavities used. Quality control testing for a filled vial (not including quality control of the bulk product) is estimated to be 12-20% of the total cost of goods.

Packaging and labeling. Many product recalls are due to mislabeling. They can devastate a company financially in terms of consumer confidence and in the reputation of both the company and the biopharmaceutical industry as a whole. Although biopharmaceuticals are not yet competing against generics, a recent consumer network survey suggested that seven of ten consumers would change a purchasing decision based on improved drug packaging. u

blog comments powered by Disqus



First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here